SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Johnell O, Kanis J 2005 Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2): S3S7.
  • 2
    Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ 2006 Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis 65: 8792.
  • 3
    Wehren LE, Magaziner J 2003 Hip fracture: Risk factors and outcomes. Curr Osteoporos Rep 1: 7885.
  • 4
    Johnell O, Kanis JA 2004 An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15: 897902.
  • 5
    Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423: 337342.
  • 6
    Hofbauer LC, Schoppet M 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490495.
  • 7
    Jones DH, Kong YY, Penninger JM 2002 Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl 2): ii32ii39.
  • 8
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sanders S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309319.
  • 9
    Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435448.
  • 10
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • 11
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 12211230.
  • 12
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S 2001 Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 35273533.
  • 13
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304309.
  • 14
    Campagnuolo G, Bolon B, Feige U 2002 Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 46: 19261936.
  • 15
    Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J 2004 Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34: 656664.
  • 16
    Mochizuki S, Fujise N, Higashio K, Tsuda E 2002 Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. J Bone Miner Metab 20: 1420.
  • 17
    Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ 2003 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18: 852858.
  • 18
    Ominsky MS, Schroeder J, Smith SY, Farrell DJ, Kostenuik PJ, Atkinson JE 2006 Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass and density in aged, ovariectomized cynomolgus monkeys. J Bone Miner Res 21: S1; S72.
  • 19
    Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM 2004 A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 10591066.
  • 20
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ for the AMG 162 Bone Loss Study Group 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821831.
  • 21
    Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16: 3141.
  • 22
    Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, Jawa V, Koren E, Swanson S 2005 Immunogenicity testing for antibodies directed against therapeutic human monoclonal antibodies using electrochemiluminescent detection. Clin Chem 51: 19831985.
  • 23
    Hochberg Y 1988 A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800802.
  • 24
    Atkinson J, Cranmer P, Saunders T, Niehaus M, Smith SY, Varela A, Ominsky MS, Cosenza ME, Kostenuik PJ 2005 AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 20: S1; S294.
  • 25
    Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ 2006 A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 12211228.